Home
About
Overview
Sharing Data
ORCID
Help
History (2)
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One. 2014; 9(9):e105919.
View in:
PubMed
subject areas
Animals
Antineoplastic Agents
Apoptosis
Bridged Bicyclo Compounds, Heterocyclic
Cell Cycle
Cell Line, Tumor
Cell Movement
Cell Proliferation
Drug Synergism
Female
Humans
Imidazoles
Lung Neoplasms
Mesothelioma
Mice
Mice, Nude
Phosphatidylinositol 3-Kinases
Phosphorylation
Proto-Oncogene Proteins c-met
PTEN Phosphohydrolase
Pyrimidines
Pyrrolidinones
Quinolines
TOR Serine-Threonine Kinases
Wound Healing
Xenograft Model Antitumor Assays
authors with profiles
Ravi Salgia
Rifat Hasina
Aliya Husain
Hedy Kindler